CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Pemetrexeddrug
Likely dose
Pemetrexed 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00523419
NCT00523419Phase 2Completed
CompareCT.gov

Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas

Eli Lilly and Company·interventional·Posted Aug 31, 2007·Updated Jun 28, 2011

In Brief

A Phase 2 clinical trial evaluating Pemetrexed for Osteosarcoma. Completed, enrolled 32 participants across 13 sites in 5 countries.

Detailed Summary

The primary purpose of your participation in this study is to help answer the following research questions, and not to provide you treatment for your condition. * To assess how well treatment with pemetrexed works for patients with your type of cancer * To assess for any side effects that might be associated with pemetrexed. * To look at the characteristics and levels of certain of your genes and proteins to learn more about osteosarcoma and how pemetrexed works in your body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteosarcoma
CountriesFrance, Germany, Italy, Spain, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2007
Enrollment StartSep 1, 2007
Primary CompletionJun 1, 2009
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.8 years ago

Interventions

Pemetrexeddrug

500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.